Equity · Healthcare
TRDA
NASDAQEntrada Therapeutics (TRDA)
This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers.
- Market cap
- 268.6M USD
- Revenue, year to Dec 2025
- 25.4M USD
- EPS, diluted, year to Dec 2025
- −3.47 USD
- 52-week range
- 5 USD – 16.08 USD
- Avg volume
- 94.3K
as of Jul 17, 2026
Have Entrada Therapeutics (TRDA) insiders bought or sold shares recently?
In the 90 days to 22 Nov 2026, Entrada Therapeutics insiders reported 24 open-market sales and no purchases (SEC Form 4); none has bought on the open market since 20 May 2026.
Form 4, 90 days to 22 Nov 2026, newest reported trade 9 Sep 2026
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 09 Sep 2026 | MPM BioVentures 2014, L.P.10% Owner | Sell | 28,837 | 206K USD |
| 09 Sep 2026 | MPM BIOVENTURES 2018, L.P.10% Owner | Sell | 28,837 | 206K USD |
| 08 Sep 2026 | MPM BioVentures 2014, L.P.10% Owner | Sell | 192,500 | 1.4M USD |
| 08 Sep 2026 | MPM BIOVENTURES 2018, L.P.10% Owner | Sell | 192,500 | 1.4M USD |
| 04 Sep 2026 | MPM BioVentures 2014, L.P.10% Owner | Sell | 38,500 | 274K USD |
| 04 Sep 2026 | MPM BIOVENTURES 2018, L.P.10% Owner | Sell | 38,500 | 274K USD |
| 03 Sep 2026 | MPM BioVentures 2014, L.P.10% Owner | Sell | 32,263 | 231K USD |
| 03 Sep 2026 | MPM BIOVENTURES 2018, L.P.10% Owner | Sell | 32,263 | 231K USD |
| 02 Sep 2026 | MPM BioVentures 2014, L.P.10% Owner | Sell | 25,131 | 181K USD |
| 02 Sep 2026 | MPM BIOVENTURES 2018, L.P.10% Owner | Sell | 25,131 | 181K USD |
| 01 Sep 2026 | MPM BioVentures 2014, L.P.10% Owner | Sell | 29,088 | 205K USD |
| 01 Sep 2026 | MPM BIOVENTURES 2018, L.P.10% Owner | Sell | 29,088 | 205K USD |
| Sold | 24 open-market sales | 991,894 | $7.20M |
Showing the 12 most recent of 24 open-market trades in this window. The figures above count all of them.
4 other filings in the window: grants, exercises, tax withholding and transfers, not trades
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 02 Sep 2026 | Doshi DipalCEO | Tax withheld | 8,724 | 62K USD |
| 02 Sep 2026 | Dowden Nathan JPresident & COO | Tax withheld | 2,528 | 18K USD |
| 02 Sep 2026 | WENTWORTH KORY JAMESChief Financial Officer | Tax withheld | 1,733 | 12K USD |
| 02 Sep 2026 | Sethuraman NatarajanPresident, Research & Develop. | Tax withheld | 2,079 | 15K USD |
Which funds hold Entrada Therapeutics (TRDA)?
8 of the 45 institutional funds we track reported a Entrada Therapeutics position for the quarter ended 30 Sep 2026 — a combined 44.9M USD; the latest of those filings landed 16 Nov 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Baker Bros. Advisors | Held (±25%) | 5,072,730 | 32.2M USD | |
| AQR Capital Management | Held (±25%) | 623,874 | 4.0M USD | −10.8% |
| Citadel Advisors | Held (±25%) | 461,737 | 2.9M USD | +17.1% |
| Millennium Management | Trimmed | 344,603 | 2.2M USD | −54.9% |
| Renaissance Technologies | Held (±25%) | 199,200 | 1.3M USD | +4.3% |
| D. E. Shaw & Co. | Added | 157,227 | 998K USD | +385.3% |
| Two Sigma Investments | Added | 111,489 | 708K USD | +140.3% |
| Point72 Asset Management | Added | 101,727 | 646K USD | +256.9% |
What has been filed or recorded for Entrada Therapeutics (TRDA)?
The filings we hold for Entrada Therapeutics, newest first: 2 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 21 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 21 Oct 2026 | Fails to deliver | Shares failed to deliver | 1,031 shares | 5K USD notional · 0.003% of shares out |
| 19 Oct 2026 | Fails to deliver | Shares failed to deliver | 1,126 shares | 5K USD notional · 0.003% of shares out |
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS −0.94 USD | Revenue $1M |
| 30 Sep 2026 | Financials | Total assets | 266.9M USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 198.3M USD | at period end |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS −1.01 USD | Revenue $1M |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS −0.95 USD | Revenue $1M |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS −3.47 USD | Revenue $25M |
| 31 Dec 2025 | Financials | Revenue | 25.4M USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | −143.8M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | −3.47 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS −1.06 USD | Revenue $2M |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS −1.04 USD | Revenue $2M |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS −0.42 USD | Revenue $21M |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS 1.68 USD | Revenue $211M |
What do people ask about Entrada Therapeutics (TRDA)?
What is Entrada Therapeutics’ market cap?268.6M
Entrada Therapeutics is worth 268.6M USD by market value as of 17 Jul 2026, which is the share price times the shares on issue from its SEC filings.
What is Entrada Therapeutics’ revenue?25.4M
Entrada Therapeutics reported revenue of 25.4M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have Entrada Therapeutics insiders bought or sold shares recently?24 sales
In the 90 days to 22 Nov 2026, Entrada Therapeutics insiders reported 24 open-market sales and no purchases (SEC Form 4); none has bought on the open market since 20 May 2026. A further 4 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders
Which funds own Entrada Therapeutics?8 of 45
8 of the 45 funds we track reported a Entrada Therapeutics position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were Baker Bros. Advisors, AQR Capital Management and Citadel Advisors. See Funds
When did Entrada Therapeutics last report earnings?−0.94
Entrada Therapeutics last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −0.94 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close)
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings
- SEC filingAbout text: the company's latest annual report filed with the SEC (Business section), summarised in our own words